Vasculitis Research: What’s on the Horizon

Vasculitis Research: What’s on the Horizon

What are some of the areas that are most promising in current vasculitis research? Dr. Jason Springer, and Dr. Peter Grayson share their own perspectives about exciting advances in earlier detection, and better treatment for vasculitis. They also discuss why the VF plays a vital role in helping to fund and develop further research.

Peter C. Grayson, MD, MSc · Head, Vasculitis Translational Research Program; Associate Director NIAMS Fellowship Program, Systemic Autoimmunity Branch, Bethesda, Maryland
Dr. Grayson is the founder and principal investigator of the Vasculitis Translational Research Program, established in 2013, and is Associate Director of the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) Fellowship Program, systemic autoimmunity branch. He serves as the representative to a major international collaboration to develop novel diagnostic and updated classification criteria in several forms of systemic vasculitis. His research focus includes biomarker discovery through gene expression profiling and other genomic techniques, disease classification, clinical epidemiology and immunology, and clinical trials in vasculitis.

Jason M. Springer, MD · Director, University of Kansas Vasculitis Clinic, Kansas City, Kansas
Dr. Springer’s family member was diagnosed with vasculitis before he started medical school. He subsequently completed his residency with Dr. Curry Koening at the University of Utah, which led to his clinical interest in vasculitis. Dr. Springer completed a fellowship at the Cleveland Clinic in general rheumatology, as well as a vasculitis fellowship. He joined the University of Kansas Medical Center six years ago to start the Vasculitis Center, and partners with the Missouri/Kansas Vasculitis Foundation chapter to host quarterly educational meetings. Dr. Springer is also Assistant Professor in Allergy, Clinical Immunology, and Rheumatology at the university’s medical center.